Shares of Danish company NovoNordisk (NOVOB.DK) are gaining nearly 11% and climbing to historic highs. The reason is the results of a study of the obesity-fighting drug Wegovy. They indicated that the drug can reduce the risk of heart disease in overweight adults by up to 20%. The market sees chances that the company is in possession of a drug that effectively helps combat chronic obesity and reduces the risk of its complications.
- In a double-blind trial, Wegovy (semaglutide) was administered to a group of 17,604 adults with obesity and cardiovascular disease (no history of diabetes, data from more than 800 centers and 41 countries) over the age of 45 for up to five years;
- To date, there are no approved weight-reduction drugs that provide effective weight control while reducing the risk of heart attack, stroke or death from cardiovascular causes;
- Novo Nordisk will apply for regulatory approval (FDA) and expanded indications for Wegovy 2.4 mg in the US and EU later this year. It will also present the scientific behind-the-scenes of the study and its results at a scientific conference, also scheduled for 2023.
NovoNordisk shares, D1 interval. Shares are climbing at ATH levels above 1200 DK per share. Source: xStation5
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appThe content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
